摘要
目的观察瑞舒伐他汀治疗不稳定型心绞痛的疗效及其对血脂,高敏C反应蛋白(high sensitive C—reaction protein,hs—CRP),同型半胱氨酸(homocy steine,Hcy)和肌钙蛋白(troponin I,cTnl)的水平的影响。方法选择2010年1月~2012年12月就诊的不稳定心绞痛患者384例,随机分为观察组和对照组,每组各192例,对照组予以辛伐他汀治疗,观察组予以瑞舒伐他汀治疗。观察2组治疗后的疗效,及对血脂,hs—CRP,Hcy和cTnl水平的变化。结果观察组的总有效率为92.19%,明显优于对照组的81.25%,差异有统计学意义(X^2=9.044,P<0.01)。治疗前2组的血脂Hcy、hs—CRP和cTnl水平差异无统计学意义,治疗后2组血脂Hcy,hs—CRP和cTnl水平较治疗前显著降低(P<0.01),HDL—C水平较治疗前显著升高(P<0.01),而观察组的降低或者升高水平较对照组更为显著(P<0.01)。结论瑞舒伐他汀治疗不稳定型心绞痛不但能降低血脂还可以减轻其炎症反应,对于稳定动脉斑块,对于不稳定型心绞痛发生,发展和预防具有重要作用。
Objective To observe the efifcacy of rosuvastatin in patients with unstable angina and its impact on the levels of lipids, high sensitive C-reactive protein (hs-CRP), homocysteine(Hcy) and troponin I (cTnI). Method 384 patients with unstable angina, from January 2010 to December 2012, were randomly divided into observation group and control group, each group had 192 cases, the control group received simvastatin, the observation group were gave rosuvastatin. The efficacy, and the levels of lipids, hs-CRP, Hcy and cTnI were observed after treatment. Results The total effective rate was 92.19%in observation group which was signiifcantly better than 81.25%in control group (χ2=9.044, P<0.01). Before treatment, the levels of TG , TC, LDL-C, HDL-C, Hcy, hs-CRP and cTnI showed no signiifcant difference, after treatment the levels of TG , TC and LDL-C, Hcy, hs-CRP and cTnI were signiifcantly lower than those before treatment (P<0.01), while, the levels of HDL-C signiifcantly increased than those before treatment (P<0.01), the reducing or increasing levels in observation group were more signiifcant compared with the control group (P<0.01). Conclusion Rosuvastatin treatment in unstable angina not only can reduce plasma lipid, but also reduce their inflammation, and stabilize the arterial plaque for unstable angina, it play an important role in development and prognosis.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第1期97-99,共3页
Chinese Journal of Biochemical Pharmaceutics
